Supplementary Figure S1 from An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers
posted on 2023-09-29, 14:20authored byBoris Guyot, Flora Clément, Youenn Drouet, Xenia Schmidt, Sylvain Lefort, Emmanuel Delay, Isabelle Treilleux, Jean-Philippe Foy, Sandrine Jeanpierre, Emilie Thomas, Janice Kielbassa, Laurie Tonon, Helen He Zhu, Pierre Saintigny, Wei-Qiang Gao, Arnaud de la Fouchardiere, Franck Tirode, Alain Viari, Jean-Yves Blay, Véronique Maguer-Satta
Supplementary Figure S1 shows the doubling time of MCF10A-CT, MC26 and M1B26 cell lines in A; the expression of the CD10 mRNA in the METABRIC cohort in B; the probability of survival of patients from the METABRIC cohort in function of CD10 expression in C; the ENI10 score of patients form the METABRIC cohort in D; the relapse-free interval of patients from the METABRIC cohort in function of the ENI10 score in E and the progression free interval in F or overall survival in G of patients form the METABRIC cohort in function of the ENI10 score and of the molecular subtype of the breast tumor.
Funding
Canceropole Rhone Auvergne
Agence Nationale de la Recherche (ANR)
Institut National Du Cancer (INCa)
Canceropole Ile de France
Region Rhone-Alpes
Ligue Nationale contre le Cancer
Fondation ARC pour la Recherche sur le Cancer (ARC)
Fondation MSD-Avenir
Dechaine ton coeur
Association Ruban Rose
Comite Feminin pour le Depistage du Cancer du Sein 74
History
ARTICLE ABSTRACT
We identified a molecular signature called ENI10 which, owing to its biological link with stem cell properties, predicts patient outcome and drugs efficiency in breast and several other cancers. ENI10 should allow early and optimized clinical management of a broad number of cancers, regardless of the stage of tumor progression.